FDA cleared Leverage the FDA 510(k) cleared eQUANT platform to target clinical laboratories seeking validated rapid AST solutions, emphasizing regulatory familiarity and quicker adoption in hospital and academic settings.

Rapid workflow Highlight the ability to cut 18+ hours from the typical workflow by eliminating subculturing, presenting a compelling value proposition to microbiology labs handling high specimen volumes and urgent clinical decisions.

Broad lab fit Position the system as budget-conscious and compatible with existing lab workflows, appealing to community hospitals, regional labs, and centralized labs seeking scalable automation without major infrastructure changes.

Leadership growth Capitalize on recent leadership hires in sales, marketing, and finance to accelerate outreach, partnerships, and enterprise deals with larger hospital networks and university-affiliated labs.

Upcoming products Prepare cross-sell and up-sell opportunities around eAST and rapid phenotypic AST platforms planned for direct PBCs and cultured isolates, targeting labs expanding from molecular to phenotypic testing.